Clinical Trial 50059

Rutland, VT 05701


This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment.

  1. Subject is aged 18 to 55 years at Screening
  2. Subject has a primary diagnosis of schizophrenia 
  3. Subject is currently being treated with monotherapy risperidone, paliperidone, aripiprazole, ziprasidone or lurasidone and has been taking this treatment with the same dosing regimen for at least 8 weeks at the time of Screening
  4. The subject has had at least 1 previous inadequate response to above antipsychotics that was dosed appropriately for at least 6 weeks
  5. The subject has not required psychiatric hospitalization, incarceration in prison, acute crisis intervention, or other increase in the level of care due to symptom exacerbation within 8 weeks of Screening 
  6. Body Mass Index (BMI) must be within 18 to 40 kg/m2

Qualified Participants May Receive:

• No-cost study medication

• No-cost study-related care from a local doctor

• NCompensation 

Available At:

Green Mountain Research Institute
198 North Main Street
Suite C-5
Rutland, VT 05701
View Clinic Location


If you or someone you care for is interested in participating and lives within 50 miles of the location shown, please complete the form below and click 'Submit'

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.